Recursion (NASDAQ:RXRX) introduced LOWE, a drug discovery software with a natural language interface, at the J.P. Morgan Healthcare Conference. LOWE, developed by Valence Labs after Recursion's acquisition of Valence Discovery, integrates Recursion's vast biological and chemical datasets and automates experiments in wet labs. It's a step towards creating 'AI scientists' for drug discovery. Recursion and NVIDIA will co-host an event to showcase LOWE, with speakers from NVIDIA, Sixth Street Capital, Genentech, American Enterprise Institute, and Verily.